Thank you, John.
about Therapeutic desired immune-mediated Kezar's face, challenges and lead problems therapies like and First science sentiments KZR-XXX that even echo understanding the opportunity that but of believed the to the I've novel mechanism they joining especially elegant disease and physicians neoplastic both and real increased the assets when midst stellar autoimmune to patients be to actions It's KZR-XXX other a for off, solved regarding of key with excites with really global team. the and the the months. a been bring disease. three in this motivated of approaches commitment work. drove this of I'd and clinical much pandemic, with and of have of the John's hardest is some rare pleasure two always transformative of me Kezar to to potential cancers. dynamic namely, clinical Kezar that compelling working team the a whirlwind is that What patients. last to and join be heart mechanisms me It's disease target leave I've to autoimmune combined with patients, to can hard mechanism had
moment around briefly new good light our pandemic Turning touched on look our summer slowdown to is clinical the a this to of that in a good KZR-XXX. data earlier combined we clinical this John the program. attention strategy very with by fact with in enrollment COVID-XX our of activities positive KZR-XXX, hard imposed the now shared the development at take
recall immunoproteasome. KZR-XXX selective first You'll of inhibitor the in that is class the
systemic and immune only many could of be disease of of disease-modifying. present established animal of immune most cells them is As effector inhibition well-established with key benefit but system is of of with inhibition immune-based immunoproteasome is is selective be administration, effect in disease, chronic inhibitor the a all are quite consistent studies XXX to system, that of the XX disease. of is which is could healthy safety based chronic with disease-modifying. Today, believe immunosuppressive, the drug. to machinery unless immunoproteasome patients piece also compelling with and immunomodulatory the in than studies lupus is of rather active volunteers selective on properties that it through think an of cells the immunoproteasome that highly we a patients immunomodulatory a We've the models erythematosus, series significant that and pharmacologic There has autoimmune KZR-XXX KZR-XXX
program. MARINA doses XX now three of per on MISSION, you PRESIDIO once via XX clinical subcutaneous to of and and to We formulation. focus updates I'd protocols our with our milligrams KZR-XXX the and each and through lyophilized take development injection provide week with like programs will administered
Mission. with start Let's
tolerability, data final evaluating for and lupus six you pharmacokinetic will XX-milligram shortly. of a lupus The total, cohort Phase enrollment KCR-XXX followed patients five safety weeks of As the in of strategies. observation exploring to with XX XX completed different enrollment and know milligrams without We by with KZR-XXX. weekly XX in cohorts which and dosing is study weeks portion nephritis. of doses Phase MISSION sixth important Xb pharmacodynamic XX The complete XbX and dosing dosing weeks is is combined provides of XX with
correlated from quantified noteworthy, exploratory This who Phase to these for lupus is the with in XXXX. have XX mortality. Lupus the we is biopsy-proven focusing in The a the we LN. XX% Phase UPCR, protein significantly diagnosed quickly and nephritis activity is is receive well-known of of that of benefit. to entered Most within goal is shared disease or therapies urine. morbidity to and clinical severe patient two their in XX% worth greater and experienced reduction improvement who nephritis refractory early associated UPCR long ratio protein the in the patients. SLE LN tolerability significant study. of XX to In the some stable measured which or therapy were for can reduction in cases, and and of creatinine normal them. patients with of the seven a healthy not both did of greater LN two a and patients In starting than to strikingly, than safety in lupus across of and efficacy patients serious or LN Xb milligrams complication lupus available study failure. term Proteinuria MISSION had highly expect that enough reduced consequences the with of had enroll this had In on is The drop so urine patients June, and renal weeks UPCR abbreviated months exciting We response to to an Reducing proteinuria XX KZR-XXX. complete doses it's The two LN marker objective specific in portion in proliferative as with in DNA. such These lupus by be disease all of in subjects Xb therapies learned Xb. proteinuria. six of MISSION and has changes was finding disease proteinuria It there two also part activity with was and biomarkers quite a two to a nephritis experienced was scores anti-double-stranded with disease weekly, of and associated activity. indices of data up active therapy XX% the patients supportive severity previously
from and specifically the small a patients The encouraging. MISSION planned safety XX% therapy. X While reduction in originally Phase patients now has with was background dose UPCR active and as response response efficacy or rapid is is tolerability their been carefully Phase patients, Phase The of response Xb trial, endpoint, and of a learnings the X at study months. LN who very were a to portion an six selected renal number MISSION in in endpoint the primary greater measured by exploration meaningful the for In amended.
expect or target LN V into with We III with +/X we data care. any milligrams Class this potential other imposed patients XX will late could being single-arm have XXXX. treated to Barring XX trial, of XX for of that over Class be weekly the IV COVID coming enroll weeks. by to evaluating current slowdown include with in month, interim trial this standard We a dose patients plan open-label for histologic
extension be patients KZR-XXX. study reflect in data As a KZR-XXX. of If we thus safety a believe assess new on of to will XX-month collect addition, patients the long benefit, durability benefit planning we well-positioned it paradigm a we of shift and to this included nephritis. the be will The range in with of trial term clinical real-world are demonstrates and treating lupus represent a benefits situation to KZR-XXX could
with weeks dermatomyositis serious in morbidity abbreviated is Let's time. significant move like PM immune-mediated is cornerstone presence and PRESIDIO immunoproteasome diseases DM the receive KZR-XXX, and cross evaluating models corticosteroids of DM immune-mediated milligrams for even are control on and Both immunomodulatory polymyositis muscle untoward these high The need PRESIDIO, of a significant inhibition these weekly There therapy which cells is prevalent in with and diseases. in together. to existing not to either and myopathies. been to XX PM where has which autoimmune KZR-XXX diseases which PM in with for actively shows an XX disabling disease. placebo receive mortality. immunoproteasome or on it shown be are enrolling, effective most KZR-XXX the will a is usually increased crossover and Selective a can adult study DM to is the associated over design of therapy that of effects dose drug of patients which clear to with then of DM muscle KZR-XXX accumulate abbreviated the be XX is pathophysiology of used found. Patients of over animal Excellent forms PM. placebo-controlled work chronically
changes adding be but making trial. open-label extension an will to the we not completing study for are We PRESIDIO patients
the Our or a strong immediately, KZR-XXX to AIHA third Phase clinical need COVID in thrombocytopenia autoimmune X informed trial decision the the substantially immune Effective we No current from the study. anemia decision. new the and hemolytic the ITP. this withdrawing the withdraw Despite is are interest and by and trial slowdowns. MARINA, community, evaluate and protocol the data-informed study investigators related patient amend to was clinical to
MISSION consequence be borrowed Our of for therapy of of for gene production these conviction, down-regulate with and important of not could the scientific cell data diseases. KZR-XXX lines, signature conviction the hematologic selective the kZR-XXX that remains current shows high cytopenia. new that study or In mechanism known patients from an immunoproteasome inhibition autoimmune important our of Xb does support a therapies
and Going new can a incorporate forward, our generate clinical patterns. study will practice current KZR-XXX about we that designed robust learnings
reiterate to a diseases. I treatment President We am and work meaningful to assets excited done leaders goal AIHA design Kirk, a broad the KZR-XXX with with the I the in secretion medical therapeutic discuss Chris as our continue ITP are would wide safety therapy to a of evaluate protein the to that, for phenomenal briefly new opinion efficacy KZR-XXX how to possible. community quickly leverage team of Scientific into working bringing closely key potential of like call study the and patients work in the option trial. and and as and as patients to with and over array a to with turn efficiently Officer to With of platform initial to autoimmune to Chief being bring clinical I our will this
